Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$690.10M+58.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pablo Legorreta
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 100
- Beta
- 0.41
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.47
Financials
Revenue
$690.10M+58.7%Net Income
$144.68M-60.6%EBITDA
$351.79M-25.1%Free Cash Flow
$686.08M+58.5%EPS (diluted)
$0.32-69.2%Shares Outstanding (diluted)
557.00M+57.3%Operating Expenses
$213.25MCash & Debt
$544.86MReturn of Capital
$191.45MRevenue by Segment (annual)
$2.38BDividend per Share
$0.23Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.38B | $770.95M | $2.33 |
| 2024 | $2.26B | $858.98M | $1.92 |
| 2023 | $2.35B | $1.13B | $3.41 |
| 2022 | $2.24B | $42.83M | $0.10 |
| 2021 | $2.29B | $619.73M | $1.49 |
| 2020 | $2.12B | $975.04M | $1.28 |
| 2019 | $1.81B | $2.35B | $6.63 |
| 2018 | $1.79B | $1.38B | $3.89 |
| 2017 | $1.60B | $1.21B | $3.42 |
| 2016 | $1.88B | $565.91M | $0.93 |
| 2015 | $1.65B | $581.43M | $0.96 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RPRX's reported EPS growth of 9.3% a year over 10 years.
- EPS in 5 years
- $2.78
- Implied price
- $47.34
- Return from $68.45
- -7.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $23.54 — -65.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 14 | 17 | 20 | 23 |
|---|---|---|---|---|---|
| -0.7% | -22.6% | -18.8% | -15.6% | -12.8% | -10.3% |
| 4.3% | -18.8% | -14.7% | -11.4% | -8.4% | -5.8% |
| 9.3% | -14.9% | -10.6% | -7.1% | -4.0% | -1.3% |
| 14.3% | -11.0% | -6.6% | -2.9% | 0.3% | 3.2% |
| 19.3% | -7.1% | -2.5% | 1.4% | 4.7% | 7.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (35)
- News247wallst.com·3d ago·Neutral
Two 64-Year-Olds Each Earn $40,000 From the Same Wells as Oil Falls 13% in a Week: the Royalty Owner Keeps Every Social Security Check, While the Working-Interest Partner Gives Up $7,220 Two neighbors, the same wells, the same $40,000 payout, and oil prices sliding fast. Yet when Social Security checks arrive next year, only one of them will find the mailbox empty. A single label on their income explains why.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·10d ago·Neutral
Royalty Pharma: Stronger Royalty Growth Supports Further Upside Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating that newer medicines are gradually reducing the portfolio's concentration. Management raised its 2026 guidance again, while new drug approvals, additional investments, and share buybacks support future growth.
View source ↗ - News (RSS)fool·14d ago·Neutral
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug Revolution Medicines has a big drug making headlines, and Royalty Pharma gets a bite of the action without doing anything at all.
View source ↗ - News (RSS)zerohedge·16d ago·Positive
FBI Arrests Meghan Markle's Father At Florida Care Home In Child Porn Case FBI Arrests Meghan Markle's Father At Florida Care Home In Child Porn Case Philippine investigators say they've counted about 7,500 images and a video - and now call the son who turned him in a "person of interest."Thomas Markle Sr., the estranged father of Meghan Markle, was arrested by federal agents in Florida on Friday morning on charges related to child sexual abuse material, two people familiar with the matter told
View source ↗ - Newszacks.com·16d ago·Positive
Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock? Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
…y Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, offering investors exposure to blockbuster therapies and megatrend-driven growth. RPRX focuses on de-risked, post-proof-of-concept assets, delivering attractive risk-adjusted returns with a return on invested capital around 15% and equity returns near 21%. The business model is defensive, uncorrelated with macro trends, and benefits from scale, high operating margins, and expert capital allocation.
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Royalty Pharma Q3 Earnings Call Highlights Royalty Pharma NASDAQ: RPRX reported third-quarter portfolio receipts of $890 million, up 9% from a year earlier, as growth in its diversified royalty portfolio offset declines in certain products. The company raised its full-year 2026 outlook for the third consecutive quarter, citing continued momentum in recurring royalty receipts.
View source ↗ - News (Marketaux)seekingalpha.com·18d ago·Neutral
Royalty Pharma plc 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:RPRX) 2026-11-04 Royalty Pharma plc 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:RPRX) 2026-11-04
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Royalty Pharma reports Q3 results
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…d full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
View source ↗ - Newszacks.com·23d ago·Neutral
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
View source ↗ - News (RSS)seekingalpha·28d ago·Neutral
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
View source ↗ - News (RSS)financialpost·31d ago·Neutral
Evolve Royalties Provides Update on Highland Valley Copper Mine Royalty (All amounts in Canadian dollars unless otherwise noted) VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Evolve Royalties Ltd. (“Evolve” or the “Company”) (CSE: EVR; OTCQX: EVRYF) announced that Teck Resources Limited (“Teck”) had reported, on October 21, 2026, that strike notice has been received in respect of the Highland Valley Copper Mine (“HVC […]
View source ↗ - Newsfool.com·31d ago·Neutral
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell Royalty Pharma buys drug royalties. Buying drug royalties provides pharmaceutical companies with cash up front while giving Royalty Pharma a long-term income stream.
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
Royalty Pharma declares fourth quarter 2026 dividend NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.
View source ↗ - News (RSS)businessinsider·44d ago·Neutral
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host...
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
View source ↗ - Newszacks.com·45d ago·Neutral
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.
View source ↗ - Newsseekingalpha.com·60d ago·Positive
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
View source ↗ - PodcastAll In·64d ago·Neutral
Silicon Valley, Royalty, Legendary Investor, Bill Gerley. Tracker could's incredible. The legend who backed Uber and Zillow, who's lived through every major text cycle for over 25 years. You're not just a commentator, right? You've been an operator. I'd love to unlock this latent human potential. There's been no time in the history of the world where you can learn faster. You can increase your surface area for luck. I'm not a big fan of these dystopian narrative. The thing to do right now is to
View source ↗ - News (RSS)businessinsider·68d ago·Neutral
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration Program (TAP), a collaborative...
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and han…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·73d ago·Neutral
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
Royalty Pharma to present at upcoming investor conferences NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
View source ↗ - News (RSS)investing·78d ago·Neutral
Royalty Pharma expects modest return despite pelacarsen trial failure
View source ↗ - News (RSS)seekingalpha·79d ago·Neutral
Royal Gold: Royalty Play With Strong Growth Profile But No Longer Cheap
View source ↗ - News (RSS)yahoo·87d ago·Neutral
Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?
View source ↗ - Newsseekingalpha.com·88d ago·Positive
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and increased scalability for higher-value transactions. The company is capitalizing on inflows into the biopharma sector, with a strategic shift toward development-stage assets that yield higher IRRs and a strong track record of regulatory approvals. Several positive catalysts are coming up. All are poised to drive incremental …
View source ↗ - News (Marketaux)insidermonkey.com·101d ago·Positive
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? A prime example unfolded when Royalt[+334 characters]
View source ↗ - Newszacks.com·101d ago·Positive
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
View source ↗
Earnings
Wed, Feb 10(in 3 months)
Consensus estimate $1.55 per share
Typical surprise +10.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$1.21 vs $1.18beat
- Wed, Aug 5$1.32 vs $1.27beat
- Wed, May 6$1.30 vs $1.21beat
- Wed, Feb 11$1.46 vs $1.29beat
- Wed, Nov 5$1.17 vs $0.99beat
- Wed, Aug 6$1.14 vs $1.03beat
Estimates and results for RPRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RPRX officers and directors.
- Bought
- —
- Sold
- $97.0m
0 trades
60 trades
- Hite Christophersold
- Coyne Terrance P.sold
- Coyne Terrance P.sold
- Coyne Terrance P.sold
- Coyne Terrance P.sold
- Urist Marshallsold
- Urist Marshallsold
- Urist Marshallsold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RPRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
